RPT-Pfizer's Hospira deal bets on price spike for specialty generics
February 06, 2015 at 07:00 AM EST
NEW YORK, Feb 5 (Reuters) - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.
